Major publicly traded medical robotics companies in South Korea posted a combined revenue increase of nearly 40% in the first half of 2026, alongside a shift to an operating profit, according to financial data analyzed by Medipana News on September 19, 2026. Data from the Financial Supervisory Service’s Electronic Disclosure System shows that aggregate revenue for seven listed medical robot firms reached 2711억7600만원 during the first six months of the year, marking a 39.90% jump from 1938억2900만원 during the same period in 2025.
First-Half 2026 Financial Performance and Earnings Turnaround
The group of seven companies swung from an aggregate operating loss of 139억8200만원 in the first half of 2025 to an operating profit of 143억3400만원 in the first half of 2026, according to Medipana News. Aggregate operating margin improved by 12.50 percentage points, moving from -7.21% to 5.29%. However, performance varied sharply across individual firms. Only three of the seven companies reported revenue growth: Future Company, 고영, and Curexo. The remaining four firms—T-Robotix, P&S Robotics, Cosmo Robotics, and Angel Robotics—experienced revenue declines.
Future Company posted the highest revenue growth rate, with sales surging 148.61% to 445억원 compared to 179억원 in the prior-year period, according to corporate disclosures cited by Medipana News. However, Future Company’s figures reflect the consolidation of Regent Partners, a financial business acquired as a major subsidiary in March 2026. 고영 reported revenue of 1615억원, up 56.46% from 1032억원, accounting for roughly 75% of the total 773억원 revenue increase across all seven companies. Curexo posted a moderate revenue increase of 8.79%, rising from 365억원 to 397억원.
Surgical Robot Growth Outpaces Rehabilitation Device Sales
Individual business segment reports show distinct divides between surgical robotics and rehabilitation or wearable device lines. Curexo reported that its medical robot business generated 183억4800만원 in the first half of 2026, a 12.0% increase from 163억8100만원 a year earlier, driven by products like the CUVIS-joint artificial joint surgical robot, CUVIS-spine spine surgery robot, and Morning Walk gait rehabilitation robot. Curexo’s medical robotics segment turned an operating profit of 8억3000만원, recovering from an operating loss in the first half of 2025.
Future Company expanded sales of its Revo-i laparoscopic surgical robot, with related revenue climbing 231.4% to 34억4600만원 from 10억4000만원, helping narrow its surgical robot operating loss from 63억2300만원 to 32억7500만원. Conversely, companies focused on rehabilitation and wearable robots faced downward pressure. P&S Robotics reported that product revenue for its Walkbot systems fell 46.0% to 24억6500만원 due to a 54.1% drop in overall export sales, which fell to 21억1900만원. Cosmo Robotics experienced a 52.9% decline in product revenue down to 24억5700만원, driven by a 67.9% drop in overseas sales. Angel Robotics saw a 33.2% drop in angel MEDI rehabilitation medical device sales down to 7억7500만원, alongside a 74.4% drop in angel SUIT wearable robot sales down to 1억9200만원.
Global Regulatory Approvals and International Expansion
To offset domestic headwinds, medical robotics firms accelerated overseas regulatory clearances and distribution agreements throughout the first half of 2026. 고영 secured Japanese regulatory approval in January for its Geniant Cranial neurosurgical robot, following prior U.S. clearance; the company's neurosurgical robots had been utilized in over 1,081 cumulative procedures as of June 2026, according to Medipana News.
Curexo gained U.S. Angel Robotics secured Malaysian medical device clearance for its angel SUIT H10 in April 2026 and completed classification procedures in Vietnam, building on earlier regulatory approvals across Thailand, Vietnam, and Malaysia.
Key Takeaways
- Aggregated Financial Swing: Combined first-half revenue for seven listed South Korean medical robotics firms rose 39.9% year-over-year to 2711억7600만원, shifting from a 139억8200만원 operating loss to a 143억3400만원 operating profit, according to financial disclosures cited by Medipana News.
- Divergent Segment Performance: Surgical robotics developers like Curexo and Future Company reported robust sales and improved profitability, while rehabilitation and wearable device makers such as P&S Robotics, Cosmo Robotics, and Angel Robotics posted declining revenues linked to drops in export sales.
- Regulatory Milestones: Major firms secured critical international clearances during the first half of 2026, including U.S. FDA and European CE MDR approvals for Curexo systems and Japanese market clearance for 고영’s neurosurgical robot platform.
Related reading